<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is a common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in <z:hpo ids='HP_0001635'>heart failure</z:hpo> and a risk factor for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Risk assessment tools can assist clinicians with decision making in the allocation of thromboprophylaxis </plain></SENT>
<SENT sid="2" pm="."><plain>This review provides an overview of current validated risk assessment tools for <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and emphasizes the importance of tailoring individual risk and the importance of weighing the benefits of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Further, this review provides details of innovative and patient-centered methods for ensuring optimal adherence to prescribed therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Prior to initiating oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy, a comprehensive risk assessment should include evaluation of associated cardiogeriatric conditions, potential for adherence to prescribed therapy, frailty, and functional and cognitive ability </plain></SENT>
</text></document>